Andy Anantha, as the President and CEO of AVA Pharma Consultants, brings over 30 years of extensive experience in pharmaceutical research and development, with a specialized focus on Chemistry, Manufacturing, and Controls (CMC) for both small molecules and biologics. His leadership is characterized by a...
Andy Anantha, as the President and CEO of AVA Pharma Consultants, brings over 30 years of extensive experience in pharmaceutical research and development, with a specialized focus on Chemistry, Manufacturing, and Controls (CMC) for both small molecules and biologics. His leadership is characterized by a proven track record in managing complex projects that span the entire drug development lifecycle, from early-phase research to NDA filing. Under his guidance, AVA Pharma has successfully delivered complete CMC packages that meet the stringent requirements of regulated pharmaceutical markets worldwide.
In his current role, Andy oversees key projects that involve the development of new chemical entities (NCEs) and generic products, ensuring compliance with regulatory affairs related to active pharmaceutical ingredients (APIs) and formulations. His expertise in organic chemistry and quality systems, combined with a deep understanding of Good Manufacturing Practices (GMP) and validation processes, positions him as a pivotal figure in the industry. Andy's ability to lead multidisciplinary teams of PhD, MS, and BS-level scientists has been instrumental in driving innovation and efficiency within the organization.
Additionally, Andy holds significant positions at Bantam Pharmaceutical in New York as Head of CMC and at Newsoara Bio-Pharma in Shanghai as Senior Vice President of Research and Development. His global perspective enhances AVA Pharma's capabilities, allowing the firm to navigate the complexities of international regulatory landscapes while delivering high-quality pharmaceutical solutions. With a strong commitment to advancing pharmaceutical science, Andy Anantha continues to shape the future of drug development through strategic leadership and a focus on excellence in every aspect of the CMC process.
